Biohaven Pharmaceutical Holding Co Ltd (BHVN) - Net Assets
Based on the latest financial reports, Biohaven Pharmaceutical Holding Co Ltd (BHVN) has net assets worth $129.50 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($466.41 Million) and total liabilities ($336.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Biohaven Pharmaceutical Holding Co Ltd (BHVN) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $129.50 Million |
| % of Total Assets | 27.77% |
| Annual Growth Rate | -10.97% |
| 5-Year Change | -45.01% |
| 10-Year Change | N/A |
| Growth Volatility | 180.32 |
Biohaven Pharmaceutical Holding Co Ltd - Net Assets Trend (2017–2025)
This chart illustrates how Biohaven Pharmaceutical Holding Co Ltd's net assets have evolved over time, based on quarterly financial data. See Biohaven Pharmaceutical Holding Co Ltd (BHVN) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Biohaven Pharmaceutical Holding Co Ltd (2017–2025)
The table below shows the annual net assets of Biohaven Pharmaceutical Holding Co Ltd from 2017 to 2025. For live valuation and market cap data, see Biohaven Pharmaceutical Holding Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $52.07 Million | -87.70% |
| 2024-12-31 | $423.44 Million | -1.06% |
| 2023-12-31 | $427.98 Million | -20.56% |
| 2022-12-31 | $538.77 Million | +468.98% |
| 2021-12-31 | $94.69 Million | +23.33% |
| 2020-12-31 | $76.78 Million | +1134.23% |
| 2019-12-31 | $-7.42 Million | -104.92% |
| 2018-12-31 | $150.92 Million | +14.36% |
| 2017-12-31 | $131.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biohaven Pharmaceutical Holding Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 188189000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.93 Billion | 3714.62% |
| Other Comprehensive Income | $8.35 Million | 16.03% |
| Other Components | $193.98 Million | 372.53% |
| Total Equity | $52.07 Million | 100.00% |
Biohaven Pharmaceutical Holding Co Ltd Competitors by Market Cap
The table below lists competitors of Biohaven Pharmaceutical Holding Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Olaplex Holdings Inc
NASDAQ:OLPX
|
$1.37 Billion |
|
Shandong Sacred Sun Power Sources Co Ltd
SHE:002580
|
$1.37 Billion |
|
Rackspace Technology Inc
NASDAQ:RXT
|
$1.37 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
$1.37 Billion |
|
Zhejiang Sanwei Rubber Item Co
SHG:603033
|
$1.37 Billion |
|
Enovix Corp
NASDAQ:ENVX
|
$1.37 Billion |
|
Xian International Medical Investment Co Ltd
SHE:000516
|
$1.37 Billion |
|
Jiangsu Zijin Rural Commercial Bank Co Ltd
SHG:601860
|
$1.37 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biohaven Pharmaceutical Holding Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 423,436,000 to 52,072,000, a change of -371,364,000 (-87.7%).
- Net loss of 738,822,000 reduced equity.
- Share repurchases of 1,833,000 reduced equity.
- New share issuances of 189,175,000 increased equity.
- Other comprehensive income increased equity by 8,269,000.
- Other factors increased equity by 171,847,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-738.82 Million | -1418.85% |
| Share Repurchases | $1.83 Million | -3.52% |
| Share Issuances | $189.18 Million | +363.3% |
| Other Comprehensive Income | $8.27 Million | +15.88% |
| Other Changes | $171.85 Million | +330.02% |
| Total Change | $- | -87.70% |
Book Value vs Market Value Analysis
This analysis compares Biohaven Pharmaceutical Holding Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 28.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.72x to 28.05x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $3.65 | $13.57 | x |
| 2018-12-31 | $3.11 | $13.57 | x |
| 2019-12-31 | $-0.15 | $13.57 | x |
| 2020-12-31 | $1.95 | $13.57 | x |
| 2021-12-31 | $2.40 | $13.57 | x |
| 2022-12-31 | $12.04 | $13.57 | x |
| 2023-12-31 | $6.01 | $13.57 | x |
| 2024-12-31 | $4.64 | $13.57 | x |
| 2025-12-31 | $0.48 | $13.57 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biohaven Pharmaceutical Holding Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1418.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 8.67x
- Recent ROE (-1418.85%) is below the historical average (-314.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-528.06 Million |
| 2020 | -154.55% | 0.00% | 0.00x | 1.45x | $-126.35 Million |
| 2021 | -225.78% | -46.23% | 3.26x | 1.50x | $-223.27 Million |
| 2022 | -105.85% | 0.00% | 0.00x | 1.23x | $-624.16 Million |
| 2023 | -95.37% | 0.00% | 0.00x | 1.20x | $-450.97 Million |
| 2024 | -199.89% | 0.00% | 0.00x | 1.45x | $-888.77 Million |
| 2025 | -1418.85% | 0.00% | 0.00x | 8.67x | $-744.03 Million |
Industry Comparison
This section compares Biohaven Pharmaceutical Holding Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $131,878,234
- Average return on equity (ROE) among peers: -44.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) | $129.50 Million | 0.00% | 2.60x | $1.37 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.66 Billion |
About Biohaven Pharmaceutical Holding Co Ltd
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more